Gemin X Report issue

For profit Phase 1 Phase 2
Founded: Montreal Canada (1998)
Status: Acquired by Cephalon (2011) → now Teva (2011)

Organization Overview

First Clinical Trial
2004
NCT00600964
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Gemin X, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hodgkin Disease (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Mastocytosis (Phase 2)

Mastocytosis, Systemic (Phase 2)

Melanoma (Phase 2)

Metaplasia (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Preleukemia (Phase 2)

Primary Myelofibrosis (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial APIs: 8